Sentences with phrase «for lung cancer treatment»
This poor performance is sadly typical for lung cancer treatments: Most are effective for between 3 and 15 percent of patients.
http://discovermagazine.com/ Not exact matches
The company has been trying to win FDA approval for Opdivo to be used as a first option treatment for non-small cell lung cancer (NSCLC).
Merck already has an FDA approved immunotherapy drug with KEYTRUDA, a treatment for non-small cell lung cancer.
The biotech specialist said that its updated phase 2 data in a study of its poziotinib candidate treatment for non-small cell lung cancer resulted in a preliminary confirmed objective response rate and potential progression - free survival benefit in patients with the EGFR Exon 20 Mutant form of the disease.
So Buck, you're cool with paying for peoples» voluntary addiction, resultant lung cancer, heart disease, emphysema and the treatment, surgery, and resource intensive long - term skilled nursing care that all entails?
«One of the toughest challenges of lung cancer is what to do for patients when the cancer comes back in an area that's been treated previously with radiation treatment,» said James J. Urbanic, M.D., lead author of the studies and a radiation oncologist at Wake Forest Baptist.
Aaron P. Mitchell, M.D., of the University of North Carolina at Chapel Hill School of Medicine, and coauthors examined FCOIs during 2014 among 125 authors of the guidelines for the treatment of breast, colon, prostate and lung cancer because those are the cancers with the highest incidence in the U.S.
If hypofractionated radiation with curative intent can reduce the treatment time for lung cancer patients by half with no greater toxicity, and with equivalent — if not better — tumor control and survival outcomes, this research could result in a change in the paradigm of how a large subset of locally advanced NSCLC patients are treated.»
The Chinese trial will enrol patients who have metastatic non-small cell lung cancer and for whom chemotherapy, radiation therapy and other treatments have failed.
Since the Lung Cancer Mutation Consortium trial began in 2009, many patients are now tested for mutated or altered genes before treatment.
«There has been a tremendous effort over the past several years to block EGFR as a treatment for lung cancer, but this therapy only works in a small subset of patients.
«Blocking both of these proteins could be a treatment that is beneficial for the majority of lung cancer patients,» said Dr. Habib, Associate Professor of Neurology and Neurotherapeutics with UT Southwestern's Peter O'Donnell Jr..
«We urgently need new treatments for lung cancer patients, and this research suggests we can boost the effectiveness of an existing drug, rather than switch to another new expensive treatment.
«Process to help personalize treatment for lung cancer patients developed.»
A one - two combo punch using two currently available drugs could be an effective treatment for the majority of lung cancers, a study by scientists with UT Southwestern's Simmons Cancer Center shows.
«Although some non-small cell lung cancer patients have increased benefit of targeted therapy or immunotherapy instead of chemotherapy, for some groups of patients with NSNSCLC, chemotherapy has been the standard treatment for more than 30 years,» Gandhi notes.
This pre-clinical study from Professor Mazzone and his colleagues reveals a new molecular axis that may offer interesting therapeutic opportunities for the treatment of pancreatic cancer, breast cancer and lung cancer, among others.
«FDG PET shows tumor DNA levels in blood are linked to NSCLC aggressiveness: Insights derived from FDG PET could improve treatment selection for patients with advanced non-small cell lung cancer.»
Phase I / II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK + non-small cell lung cancer (NSCLC), with 58 of 78 ALK + patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.
Few existing treatments offer durable survival benefits for patients whose NSCLC has spread past the lungs, due in part to the aggressive nature of lung cancer and its propensity to progress, even following treatment.
Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements and subsequent biomarker - guided treatment is cost - effective compared with standard chemotherapy treatment without any molecular testing in the metastatic non-small cell lung cancer (NSCLC) setting in the United States.
Pembrolizumab is set to become a new option for first line treatment of patients with advanced lung cancer and high PD - L1 expression, according to the results of the phase III KEYNOTE - 024 trial presented at the ESMO 2016 Congress in Copenhagen and published in the New England Journal of Medicine.
«Potential new treatment approach for lung cancer.»
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred treatment option for patients with advanced non-small cell lung cancer (NSCLC) who have mutations in the EGFR gene.
This will establish sequential crizotinib followed by a second generation ALK inhibitor as the standard treatment for patients with metastatic ALK positive lung cancer.»
P: We found discodermolide [a drug from Discodermia, a sponge found in the Caribbean, the Bahamas, and the Gulf of Mexico], and it's gone through phase I clinical trials for treatment of solid tumors such as ovarian, pancreatic, breast, colon, or lung cancers.
In the group that received targeted treatment for ALK - positive lung cancer, each category of tumor reduction was associated with corresponding gains in PFS and OS.
«This study demonstrates the value of testing lung cancer tissue for an ALK rearrangement, and it underscores the potential of cancer genomics to target cancer treatments to each patient,» says the study's senior author, Pasi A. Jänne, MD, PhD, who is the director of the Lowe Center for Thoracic Oncology of Dana - Farber.
«First - line immunotherapy treatment can improve survival for subset of lung cancer patients: Results of phase III global clinical trial show that 75 percent of stage IV lung cancer patients with both complex tumor mutations and PDL - 1 positive status respond to nivolumab.»
Right now, the tests, which are available from several companies, mostly aid in treatment decisions for people already diagnosed with a particular form of cancer, such as prostate or lung.
Lung cancer in particular has become the «poster child» for how research and treatment have changed, says Charles Swanton, a research oncologist at the Francis Crick Institute in London, England.
Treatments for diabetes, smoking, Alzheimer's disease and lung cancer are just a few of the potentially lifesaving cures Scientific American has chosen to highlight in this year's roundup of drugs you've never heard of, despite their potentially huge impact on global health.
Knowing more about the activation process has led researchers to be able to induce greater vulnerability by cancer cells to an existing first - line treatment for cancers (mainly lung) driven by a receptor called EGFR.
Although she never received any medical or surgical treatment for the deadly cancer invading her lungs, six weeks after starting psychosynthesis, her tumors began to shrink.
«Rapid advancements in genetic testing offer new treatment options for patients with advanced lung cancer.
«But even more importantly, for patients, our ability to identify the similarities could allow treatments for other cancers like lung to be used for certain breast cancers down the road.»
Moving forward, they plan to continue testing derivatives of HIPP for the treatment of colon cancer and also see if their findings extend to breast, lung, ovarian and prostate cancers.
Biopsies of pulmonary lesions are essential for increasing the accuracy of diagnosis and treatment for respiratory illnesses such as lung cancer.
«For about 80 percent of our patients with lung cancer, we don't have tests like [the one for] ALK to tell us what treatments will work best,» Shaw saFor about 80 percent of our patients with lung cancer, we don't have tests like [the one for] ALK to tell us what treatments will work best,» Shaw safor] ALK to tell us what treatments will work best,» Shaw says.
«We wanted to look at the patients» tumor and immune system prior to treatment and examine it again after treatment for changes,» said Patrick Forde, first author and co-principle investigator of the trial and a lung cancer oncologist in the Bloomberg ~ Kimmel Institute of Cancer Immunothcancer oncologist in the Bloomberg ~ Kimmel Institute of Cancer ImmunothCancer Immunotherapy.
The therapy, reported in the Aug. 17 issue of Nature Communications, offers the hope of an effective treatment for intractable metastatic cancers including those of the colon and lung.
The drugs are already approved for treatment of patients with advanced breast cancer as well as ovarian, pancreatic and certain lung cancers.
Cancer Research UK scientists have found a drug combination that can trigger the self - destruct process in lung cancer cells — paving the way for new treatments, according to research that will be presented at the National Cancer Research Institute (NCRI) Cancer Conference in LiveCancer Research UK scientists have found a drug combination that can trigger the self - destruct process in lung cancer cells — paving the way for new treatments, according to research that will be presented at the National Cancer Research Institute (NCRI) Cancer Conference in Livecancer cells — paving the way for new treatments, according to research that will be presented at the National Cancer Research Institute (NCRI) Cancer Conference in LiveCancer Research Institute (NCRI) Cancer Conference in LiveCancer Conference in Liverpool.
«Programs that provide treatment for lung cancer also must measure their performance actively and carefully in order to improve the quality of care and improve patients» chances of survival.»
Researchers at Norris Cotton Cancer Center have found an antibody that may be used in future treatments for recurrent small - cell lung cancer, which currently has no effective thCancer Center have found an antibody that may be used in future treatments for recurrent small - cell lung cancer, which currently has no effective thcancer, which currently has no effective therapy.
«Antibody - targeted treatment developed for recurrent small - cell lung cancer.»
«It takes too long for patients who have suspected lung cancer to get final treatment, and too many patients skip vital steps needed to decide the best possible treatment,» said Dr. Osarogiagbon.
«Researchers inhibit tumor growth in new subtype of lung cancer: Insight into tumor suppressing and tumor promoting mechanisms offers potential for new treatments.»
«Lung cancer care is complicated, and all key specialists must be actively engaged early on with each patient to determine the best sequence of tests and treatment for each individual,» said Dr. Osarogiagbon.
Using only patients who had surgery for suspected lung cancer, the researchers examined how long it took to begin care and what steps were taken to determine appropriate treatment.